Cargando…

Can the RBD mutation R346X provide an additional fitness to the “variant soup,” including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?

Detalles Bibliográficos
Autores principales:	Chatterjee, Srijan, Bhattacharya, Manojit, Dhama, Kuldeep, Lee, Sang-Soo, Chakraborty, Chiranjib
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015894/ https://www.ncbi.nlm.nih.gov/pubmed/36938362 http://dx.doi.org/10.1016/j.omtn.2023.02.030

Ejemplares similares

The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties – an alarming global threat of a surge in COVID-19 cases again?
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant
por: Islam, Md. Aminul, et al.
Publicado: (2023)

Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
por: Li, Dedong, et al.
Publicado: (2023)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Recently emerged omicron subvariant BF.7 and its R346T mutation in the RBD region reveal increased transmissibility and higher resistance to neutralization antibodies: need to understand more under the current scenario of rising cases in China and fears of driving a new wave of the COVID-19 pandemic
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Designing, characterization, and immune stimulation of a novel multi-epitopic peptide-based potential vaccine candidate against monkeypox virus through screening its whole genome encoded proteins: An immunoinformatics approach
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

Cases of BA.2.75 and recent BA.2.75.2 subvariant of Omicron are increasing in India: Is it alarming at the global level?
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Molnupiravir’s mechanism of action drives “error catastrophe” in SARS-CoV-2: A therapeutic strategy that leads to lethal mutagenesis of the virus
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7
por: Zhang, Yanfang, et al.
Publicado: (2023)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Emergence BQ.1 and BQ.1.1 as newly identified omicron subvariants: current scenario and future outlook – an update
por: Akash, Shopnil, et al.
Publicado: (2023)

The D614G mutation helps to increase the transmissibility and reduce the virulence of SARS-CoV-2 variants through natural selection
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

Omicron variant (B.1.1.529) of SARS-CoV-2: understanding mutations in the genome, S-glycoprotein, and antibody-binding regions
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

A comprehensive analysis of the mutational landscape of the newly emerging Omicron (B.1.1.529) variant and comparison of mutations with VOCs and VOIs
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB
por: He, Qingwen, et al.
Publicado: (2023)

Continent-wide evolutionary trends of emerging SARS-CoV-2 variants: dynamic profiles from Alpha to Omicron
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Integrative Bioinformatics Approaches Indicate a Particular Pattern of Some SARS-CoV-2 and Non-SARS-CoV-2 Proteins
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Recently spreading human monkeypox virus infection and its transmission during COVID-19 pandemic period: A travelers' prospective
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

A call for a novel and next-generation vaccine against monkeypox disease
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2023)

Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of Omicron BQ.1, BQ.1.1, XBB and XBB.1 variants
por: Popovic, Marko
Publicado: (2023)

Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1
por: Miller, Jessica, et al.
Publicado: (2023)

Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination
por: Ju, Bin, et al.
Publicado: (2023)

Monkeypox in South-East Asia: Is an alarming bell for this region? – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Artificial intelligence–enabled clinical trials might be a faster way to perform rapid clinical trials and counter future pandemics: lessons learned from the COVID-19 period
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
por: Carr, Edward J, et al.
Publicado: (2023)

Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Recombinant SARS-CoV-2 variants XD, XE, and XF: The emergence of recombinant variants requires an urgent call for research – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Evolution, epidemiology, geographical distribution, and mutational landscape of newly emerging monkeypox virus
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Monkeypox virus vaccine evolution and global preparedness for vaccination
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Evaluation of differentially expressed genes during replication using gene expression landscape of monkeypox-infected MK2 cells: A bioinformatics and systems biology approach to understanding the genomic pattern of viral replication
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Quantum computing on nucleic acid research: Approaching towards next-generation computing
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
por: Zhu, Airu, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
por: Bellusci, Lorenza, et al.
Publicado: (2023)

Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: Current update
por: Bhattacharya, Manojit, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ojg59ovcbbjfbn9nb59cpkbgpt